Search

Zai Lab Ltd ADR

Closed

SectorHealthcare

26.16 -2.68

Overview

Share price change

24h

Current

Min

25.29

Max

26.92

Key metrics

By Trading Economics

Income

191K

-51M

Sales

6.7M

106M

EPS

-0.46

Profit margin

-47.808

Employees

1,784

EBITDA

-2.1M

-46M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+49.94% upside

Dividends

By Acuity

Next Earnings

5 lis 2026

Market Stats

By TradingEconomics

Market Cap

805M

2.9B

Previous open

28.84

Previous close

26.16

News Sentiment

By Acuity

38%

62%

111 / 339 Ranking in Healthcare

Zai Lab Ltd ADR Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

4 wrz 2026, 23:40 UTC

News

DocuSign Inc. reported strong second-quarter results and raised guidance, yet shares are trading lower in after-market hours amid valuation concerns and economic context.

4 wrz 2026, 23:35 UTC

News

AAP shares lower in after-market hours on analyst rating updates.

4 wrz 2026, 23:27 UTC

News

Photronics Inc shares traded lower in after-market hours amid a securities class action lawsuit alleging fraud related to its product pipeline and demand stability.

4 wrz 2026, 23:20 UTC

News

Monster Beverage appoints Matthew S. Burroughs as Chief Accounting Officer and Deputy CFO, with shares rising in after-market trading.

4 wrz 2026, 23:10 UTC

News

Northrop Grumman was awarded a $508.49 million contract for flight test support by the U.S. Department of Defense, shares trading higher in after-market hours.

4 wrz 2026, 23:05 UTC

News

Pomerantz LLP filed a class action lawsuit against Replimune Group Inc for alleged securities fraud, contributing to a decline in shares during after-market hours.

4 wrz 2026, 23:02 UTC

News

Illumina Inc will join the S&P 500 index effective September 21, 2026, following an announcement by Dow Jones Indices. Shares are trading higher after the news.

4 wrz 2026, 23:02 UTC

Social Media
News

Star Bulk Carriers announced a parallel listing on Euronext Athens and an equity offering. Shares are lower in after-market hours following the news.

4 wrz 2026, 23:02 UTC

News

Ionis Pharmaceuticals shares declined in after-market trading following Novartis' announcement of the failed pelacarsen Phase 3 study to reduce cardiovascular events.

4 wrz 2026, 23:00 UTC

News

Bloom Energy shares are higher in after-market trading following its inclusion in the S&P 500, effective September 21, 2026.

4 wrz 2026, 23:00 UTC

News

FirstEnergy shares rise in after-market trading following Potomac Edison's $52.8 million rate adjustment proposal to enhance electric system reliability in Maryland.

4 wrz 2026, 23:00 UTC

News

Campbell's Co announced a restructuring plan, cutting 13% of salaried jobs and closing two plants. Shares are trading higher in after-market hours.

4 wrz 2026, 22:51 UTC

Correlated Moves
News

Shares rose in after-market trading amid strength in oil sector.

4 wrz 2026, 20:08 UTC

News

Planet Fitness Inc. is facing a securities class action lawsuit alleging misleading statements on customer growth, contributing to a decline in its stock during Friday's session.

4 wrz 2026, 20:08 UTC

News
Correlated Moves

Marten Transport Ltd shares are higher, supported by a broader transportation sector rally and an amended credit facility increasing the letters-of-credit sublimit to $50 million.

4 wrz 2026, 20:08 UTC

News

Jefferies Financial Group's shares are higher as it maintains "buy" ratings and raises price targets for several banks, including Barclays and Lloyds.

4 wrz 2026, 20:08 UTC

News

El Pollo Loco Holdings to participate in two investor conferences this month. Shares are trading higher, reflecting positive sentiment despite earlier session pullback.

4 wrz 2026, 20:08 UTC

News

Intuitive Surgical shares declined to $365.21, marking a four-week low. Ongoing market challenges contributed to the stock's downward movement during the session.

4 wrz 2026, 20:08 UTC

News
Social Media
Macro Event

McDonald's shares hit a 52-week low amid ongoing challenges, including high menu prices like $15 for an Egg McMuffin, reflecting a broader market decline.

4 wrz 2026, 20:08 UTC

News

OrthoPediatrics Corp shares are lower amid broader market declines and selling pressure following a strong jobs report. A major shareholder's recent sale adds to negative sentiment.

4 wrz 2026, 20:08 UTC

Social Media
Macro Event
News
Correlated Moves

Intel shares are higher as demand for CPUs surges, driven by AI workloads. Despite a price target cut to $92, investor sentiment remains positive.

4 wrz 2026, 20:08 UTC

News
Correlated Moves
Social Media

Advanced Micro Devices is rising as AI demand boosts projections for its EPYC CPUs, aided by partnerships like Microsoft’s Project Zenith.

4 wrz 2026, 20:08 UTC

News

Globus Medical Inc received CE mark approval for its Excelsius3D system, enabling sales in the EU and U.K. Shares are gaining during Friday's session.

4 wrz 2026, 20:08 UTC

News

PVH Corp reported a second-quarter loss of $102.9 million but shares are higher today, rebounding after an earlier dip during the session.

4 wrz 2026, 20:08 UTC

News
Correlated Moves

Douglas Dynamics declared a quarterly dividend of $0.295 per share, with shares rising today alongside Astec Industries' notable gain.

4 wrz 2026, 20:08 UTC

Macro Event
Social Media
News

Dell Technologies reported strong quarterly earnings, with revenue rising significantly. The stock reached a record high amid positive sentiment following the earnings beat.

4 wrz 2026, 20:08 UTC

News

Ollie's Bargain Outlet reported Q2 EPS of $1.42, surpassing estimates. Shares are higher amid positive sentiment following the earnings announcement.

4 wrz 2026, 20:08 UTC

News

Airbnb Inc. shares are declining as the EU proposes regulations on short-term rentals to address affordable housing shortages in tourist areas.

4 wrz 2026, 20:08 UTC

News

UnitedHealth Group will cut prior-authorization requirements across plans starting October 1. Shares are lower today, in line with broader market declines.

4 wrz 2026, 20:08 UTC

News

Teladoc Health Inc shares are lower today amid broader market declines following a strong jobs report raising concerns over tighter monetary policy.

Peer Comparison

Price change

Zai Lab Ltd ADR Forecast

Price Target

By TipRanks

49.94% upside

12 Months Forecast

Average 39.33 USD  49.94%

High 45 USD

Low 36 USD

Based on 3 Wall Street analysts offering 12 month price targets forZai Lab Ltd ADR - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

3 ratings

3

Buy

0

Hold

0

Sell

Sentiment

By Acuity

111 / 339 Ranking in Healthcare

News Sentiment

Bullish Evidence

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Zai Lab Ltd ADR

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis. The company also develops Tumor Treating Fields, a portable device for delivery of electric fields; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Tisotumab vedotin, an antibody drug conjugate; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, and pancreatic cancer; and Bemarituzumab to treat gastric and gastroesophageal junction cancer patients. In addition, it develops Sulbactam/durlobactam, a combination of a beta-lactam antibiotic and a beta-lactamase inhibitor for the treatment of serious infections caused by Acinetobacter; KarXT for the treatment of psychiatric and neurological conditions. It has license and collaboration agreement with Tesaro, Inc. to develop, manufacture, and commercialize niraparib; NovoCure to develop and commercialize Tumor Treating Fields; Deciphera to develop and commercialize ripretinib; Paratek Bermuda Ltd. to develop, manufacture, and commercialize omadacycline; argenx, to develop and commercialize efgartigimod; BMS to develop and commercialize tisotumab vedotin and repotrectinib; Mirati to research, develop, manufacture, and commercialize adagrasib; Amgen to develop and commercialize bemarituzumab; and Innoviva to develop and commercialize Sulbactam-Durlobactam; Karuna to develop and commercialize KarXT; and strategic collaboration with Pfizer for XACDURO. The company was incorporated in 2013 and is headquartered in Shanghai, China.
help-icon Live chat